Another novel cancer vaccine approach is to stimulate anti-tumor immunity via STING activation in Batf3-dependent dendritic cells (DC) through the use of replication-attenuated VV vectors.
STING has been recognized as an activator of immune responses by TBK1/IRF3 and NF-<i>κ</i>B pathways, and it is suggested to play critical roles in host defense, autoimmune diseases, and tumor immunity.